In addition, the anti-OSMRβ antibody vixarelimab (KPL-716) is now under a clinical trial for the treatment of prurigo nodularis (ClinicalTrials.gov Identifier: NCT03816891) [81]. The gene discussed is OSMR; the disease is prurigo nodularis.